在非洲提升当地疫苗制造能力 - - 机遇,优先事项和挑战
Joachim Doua1, Nicaise Ndembi2, Jochen Auerbach3
1Centre for Advanced Research & Development (CARED), Keizerslaan 10, 1000, Brussels, Belgium; Coalition for Epidemic Preparedness Innovations (CEPI), Skøyen Atrium, Askekroken 11, 0277, Oslo, Norway.
Vaccine
|February 6, 2025
概括
非洲使用全球25%的疫苗,但仅生产1%,这凸显了当地生产的必要性. 扩大非洲疫苗生产规模,专注于优先疫苗和利用新举措,对于卫生安全至关重要.
科学领域:
- 全球卫生健康 全球卫生健康
- 疫苗学 疫苗学 疫苗学
- 制药制造业 制药制造业 制药制造业
背景情况:
- 非洲占全球疫苗消费量的25%,但只有1%在当地制造.
- 随着COVID-19大流行,非洲的疫苗供应和分配出现了严重的不平等现象.
- 对于生产活性疫苗成分和利用先进技术平台,当地产能有限.
研究的目的:
- 分析非洲疫苗制造的现状.
- 根据需求和疾病负担,确定当地生产的优先疫苗.
- 探索促进非洲疫苗制造能力的机遇和挑战.
主要方法:
- 审查非洲各地现有的疫苗制造设施和能力.
- 对疫苗市场需求,疾病流行率和技术需求的分析.
- 确定扩大本地生产的关键推动因素和挑战.
主要成果:
- 非洲11家制造商中有10家拥有配方/填充/完成能力;活性成分生产很少.
- 南非和塞内加尔拥有端到端的制造能力.
- 当地生产的优先疫苗包括麻疹-红疹,黄热病,霍乱,轮状病毒和脑膜炎球菌.
结论:
- 加强监管系统,研发和劳动力发展对于大陆疫苗制造至关重要.
- 优惠采购和有针对性的投资是必要的推动因素.
- 非洲疫苗制造加速器提供了一个重要的机会,但持续的资金是关键的挑战.
相关概念视频
Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...


